�������

News from ������� Langone Health

What Patients With Genitourinary Cancers Should Know After ASCO 2025. (Cure Today)

(6/11) Joshua K. Sabari, MD, assistant professor, Department of Medicine, Division of Hematology and Medical Oncology, Perlmutter Cancer Center, and Dr. Daniel V. Araujo, a medical oncologist at University of Florida Health, discussed key insights from the 2025 ASCO Annual Meeting on genitourinary oncology, including the AMPLITUDE trial findings and the role of circulating tumor DNA (ctDNA) in bladder cancer.

Lung Cancer Drugs Show Promise For Treatment-Resistant Melanoma. (Managed Healthcare Executive)

(6/11) New research led by Milad Ibrahim, PhD,  postdoctoral fellow, Ronald O. Perelman Department of Dermatology, suggests that EGFR inhibitors, such as Erbitux and Gilotrif, may be effective against drug-resistant melanoma with neurofibromin 1 (NF1) mutations, affecting 27% of patients, as these drugs reduced tumor growth in lab studies and mouse models; Iman Osman, MD, associate dean, Clinical Research Strategy, and the Rudolf L. Baer Professor of Dermatology, and professor, Departments of Medicine and Urology, said, “Our study results reveal a unique vulnerability in melanoma patients with neurofibromin 1 mutations, that an overexpression of the epidermal growth factor receptor pathway is essential for their survival and growth.”

EGFR Inhibitors As A Solution For NF1-Mutant Melanoma. (Technology Networks)

(6/11) A study led by �����о��� Langone Health and its Perlmutter Cancer Center, published in Cancer Research, reveals that increased EGFR activity in NF1 mutant melanoma cells may explain resistance to immunotherapy, suggesting EGFR inhibitors like cetuximab and afatinib as potential treatments, with study lead investigator Milad Ibrahim, PhD,  postdoctoral fellow, Ronald O. Perelman Department of Dermatology, saying, “There is a pressing need for new drug therapies for melanoma patients with neurofibromin 1 mutations that do not respond to the latest immunotherapy, and for which there are no subsequent effective treatment options.” Study senior investigator Iman Osman, MD, associate dean, Clinical Research Strategy, and the Rudolf L. Baer Professor of Dermatology, and professor, Departments of Medicine and Urology, also spoke on the study’s findings.

Dr Sabari On C-MET As A Potential Biomarker Of Response In EGFR Wild-Type NSCLC. (OncLive)

(6/11) Joshua K. Sabari, MD, assistant professor, Department of Medicine, Division of Hematology and Medical Oncology, Perlmutter Cancer, discussed the potential of c-MET as a biomarker for patients with nonsquamous, EGFR wild-type advanced NSCLC, saying, “We want to look at [c-MET] as a biomarker for patients who may benefit from [telisotuzumab vedotin],” and highlighted findings from the phase 2 LUMINOSITY trial, which showed objective response rates of 34.6% and 32.8% in patients with high c-MET overexpression after different chemotherapy regimens, suggesting c-MET expression level as a key predictor of therapeutic response.

Stacy Loeb, MD, MSc, PhD (Hon), Discusses The Nuances Of Prostate Cancer Screening. (Urology Times)

(6/11) In a recent interview, Stacy Loeb, MD, professor, Departments of Urology and Population Health, Perlmutter Cancer Center, discussed prostate-specific antigen (PSA) screening guidelines for older men, illustrating with President Joseph R. Biden’s case the potential pitfalls of stopping routine PSA screening around age 70 or 75, as recommended by guidelines, since stopping screening at 72 may have delayed the detection of aggressive prostate cancer, while also acknowledging the risks of continued screening, such as false positives and overtreatment, and advocating for individualized decision-making based on life expectancy, health status, and patient preferences.

I Attended The World’s Biggest Cancer Conference. Doctors Gave Standing Ovations To 2 Major Breakthroughs. (Insider)

(6/11) At the American Society of Clinical Oncology annual meeting, Canadian scientists presented findings that a prescribed exercise routine could surpass ongoing chemotherapy in effectiveness for colon cancer patients, with Paul E. Oberstein, MD, associate professor, Department of Medicine, Division of Hematology and Medical Oncology, Perlmutter Cancer Center, saying, “This is so new and different and really incredible,” while considering implementing a program with potential funding from cancer philanthropy groups.

ASHP Awards 19 Hospital Pharmacy Leaders, Employees. (Becker's Hospital Review)

(6/11) The American Society of Health-System Pharmacists has named Amisha Arya, PharmD, BCSCP, CJCP, regulatory and compliance, as one of the 2025 Fellows, recognizing her commitment to excellence and contributions to the field.

GPT-4 AI Model Outperforms Traditional Tools In Predicting cSCC Outcomes. (Managed Healthcare Executive)

(6/11) A study published in JAMA Dermatology reveals that a risk prediction tool for cutaneous squamous cell carcinoma (cSCC), utilizing the GPT-4 AI model known as AIRIS, surpasses existing systems like AJCC8 and BWH in predicting poor outcomes, with testing conducted on 2,379 biopsy-proven cases from ������� Langone Health and Mayo Clinic; AIRIS demonstrated higher predictive power, evidenced by AUC values of 0.69 (local recurrence), 0.81 (nodal metastasis), 0.85 (distant metastasis), and 0.80 (disease-specific death), though authors caution about biases and the need for further validation and integration of multimodal data to enhance personalized risk predictions.

This “Healthy” Fat May Secretly Be Fueling Obesity. (Science Daily)

(6/11) A study published in Cell Reports by researchers including those from ������� Grossman School of Medicine and the University of Oklahoma College of Medicine, found that oleic acid, a monounsaturated fat commonly found in olive oil, may contribute to obesity by increasing the production of fat cells.

A Doctor Shares How Running May Actually Benefit Your Knees. (Prevention Magazine)

(6/11) Running is an accessible and affordable exercise that can improve cardiovascular and bone health, though those with arthritis or cartilage damage should consult a physician before starting, according to experts including Melissa Mastoridis, MS, E.P-C, exercise physiologist, Orthopedic Center, Sports Performance Center, who advises starting slowly to avoid injury, emphasizing the importance of dynamic warm-ups and proper form.

Americans Are Obsessed With Taking The ‘Work’ Out Of Working Out. (Insider)

(6/12) A recent exploration into the use of electro-muscle stimulation (EMS) suits, which promise to deliver the results of a four-hour workout in just 25 minutes, reveals skepticism about their efficacy, as experts including Melanie R. Jay, MD, professor, Department of Medicine, Division of General Internal Medicine and Clinical Innovation, and Department of Population Health, suggest that such devices offer minimal benefits compared to traditional exercise; Dr. Jay says these products do not provide “the same benefits as exercise or losing weight and maintaining weight loss.”

7 Supplements With The Most Health Risks, According To Doctors. (TODAY)

(6/11) Julia Adamian, MD, clinical professor, Department of Medicine, Division of General Internal Medicine and Clinical Innovation, section chief, General Internal Medicine and Clinical Innovation, highlights the potential dangers of supplements like black cohosh, turmeric, and green tea extract, which can cause liver damage, interact with medications, and lead to other side effects, stressing the importance of consulting a doctor before use and saying, “What makes some (supplements) dangerous is the fact that most people think they cannot hurt and are always safe, so the suspicion is that a large amount of patients do not mention it to their doctor.”

Do Wrinkle Patches Actually Work? Dermatologists Weigh In. (TODAY)

(6/11) Wrinkle patches, gaining popularity on social media, are designed to minimize facial fine lines by restricting skin movement and retaining moisture, with Mary L. Stevenson, MD, associate professor, the Ronald O. Perelman Department of Dermatology, explaining that they can prevent wrinkle formation by limiting skin mobility and moisture loss, though their effects are likely short-term unless used regularly.

A Study Says Gray Hair May Be Reversible. (Popular Mechanics)

(6/11) A study from �����о��� Grossman School of Medicine, published in Nature, identifies that graying hair may result from melanocyte stem cells (McSCs) becoming immobilized in the hair follicle bulge compartment, preventing them from maturing into pigment cells; Mayumi Ito Suzuki, PhD, professor, the Ronald O. Perelman Department of Dermatology, and Department of Cell Biology, said, “It is the loss of chameleon-like function in melanocyte stems cells that may be responsible for graying and loss of hair color,” while Qi Sun, postdoctoral researcher, added, “Our study adds to our basic understanding of how melanocyte stem cells work to color hair,” suggesting potential pathways to reverse or prevent graying hair by restoring McSC mobility.

Could Promptathons Unlock AI For Government? (Government Technology)

(6/11) State and local governments, including Pennsylvania, are exploring how artificial intelligence can transform operations, with initiatives like Pennsylvania’s yearlong pilot program using ChatGPT Enterprise, which involved 175 state employees and reported 85% positive experiences despite challenges in learning to interact with AI; promptathons, akin to hackathons, focusing on crafting AI instructions, have been successful in various sectors, including a 2024 event at �����о��� Langone Health, and experts like Rhode Island’s CISO Nathan Loura and former New York Deputy CIO Jennifer Lorenz suggest that while AI skills are crucial now, they may become less central as AI systems advance.

George Annas, Ethicist And Advocate For Patients’ Rights, Dies At 79. (Washington Post)

The (6/11) George Annas, an influential figure in the intersection of medicine, ethics, and law, particularly known for shaping the modern concept of patients’ rights, passed away at 79 in Boston. Annas, who was not a physician but a prominent health lawyer, contributed significantly to healthcare discussions, particularly around patient autonomy and the right to refuse treatment; Art Caplan, PhD, the Drs. William F. and Virginia Connolly Mitty Professor of Bioethics, Department of Population Health, Division of Medical Ethics, noted, “He was one of the loudest voices in taking a human rights framework and applying it to health matters and health law.”